The amount of science‑related real estate occupied across the UK’s Golden Triangle of Cambridge, Oxford and London has moved unevenly over the past year, according to fresh figures from Cushman & Wakefield. While the second quarter of 2026 recorded a total of 175,000 sq ft taken, this represented a 57% fall from the 242,200 sq ft transacted in Q1 2026.
Sharp swings but an underlying pipeline
Although the Q2 total aligns broadly with the previous 12‑month comparison — around 168,300 sq ft — activity has been highly variable. The market fell to just 50,300 sq ft in Q3 2025 before surging to 556,700 sq ft in Q4 2025, illustrating how a handful of large transactions can reshape quarterly totals.
Looking ahead to Q3 2026, data points to renewed growth. Cushman & Wakefield recorded a major deal earlier in the week — a 300,000 sq ft agreement with GlaxoSmithKline — which on its own would substantially lift upcoming receipts. Excluding that transaction, the consultancy notes there remained 479,200 sq ft of science space under offer at the end of Q2 2026, in addition to specific pipelines of:
- 141,900 sq ft in Cambridge
- 242,000 sq ft in London
- 95,300 sq ft in Oxford
Drivers and international context
Cushman & Wakefield link this pattern to broader capital market movements, pointing to improving conditions in US biotech public markets as a contributing factor. The Nasdaq biotechnology index recently hit an intraday high of 6,878.8, having gained 47% over the prior 12 months — a dynamic that can boost confidence among US investors and strategic partners considering late‑stage UK companies.
“Many of the region’s leading life sciences businesses are internationally connected, with US facing investors, strategic partners and potential nasdaq pathways. A stronger US public market environment should therefore support confidence toward later stage UK companies and help sustain the pipeline of spinouts, start ups and scale ups across London, Oxford and Cambridge.”
The commentary underlines how internationally linked capital flows and public market sentiment can indirectly affect occupier demand for laboratory and office space in the Golden Triangle.
Implications for the UK science ecosystem
Volatility in quarterly take‑up complicates short‑term planning for developers and occupiers, but the sizeable stock under offer signals sustained interest. For city and regional planning, the pattern underscores the importance of flexible lab‑ready space and of managing infrastructure to accommodate spikes in demand driven by large corporate relocations or funding events.
| Quarter | Sq ft transacted |
|---|---|
| Q3 2025 | 50,300 |
| Q4 2025 | 556,700 |
| Q1 2026 | 242,200 |
| Q2 2026 | 175,000 |
Separately, venture capital flows into UK life sciences were reported to have more than doubled to over £2bn in Q2 2026, a strong quarterly performance that can underpin future occupier demand by fuelling company growth and scaling needs.
The interplay between public markets, private funding and physical space demand will remain central to how the Golden Triangle evolves. While single large deals can produce dramatic quarter‑to‑quarter movements, the volume of space under offer and growing capital inflows suggest cautious optimism for a recovery in occupier activity in the coming quarters.
